Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ).
Shanghai Junshi Biosciences Co., Ltd. announced that its subsidiary, Shanghai JunTop Biosciences Co., Ltd., received acceptance from the National Medical Products Administration for its investigational new drug application for JT118, a recombinant protein vaccine aimed at preventing monkeypox virus infection. This development marks a significant step in the company’s collaborative efforts with prominent Chinese research institutions to address the lack of approved monkeypox vaccines in China, potentially strengthening its position in the pharmaceutical industry.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a pharmaceutical company based in China, focusing on the development of innovative drugs, particularly in the field of biosciences. The company is involved in research and development of vaccines and therapeutics, with a market focus on addressing unmet medical needs.
Average Trading Volume: 4,366,626
Technical Sentiment Signal: Buy
Current Market Cap: HK$36.34B
For detailed information about 1877 stock, go to TipRanks’ Stock Analysis page.